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Relapse in schizophrenia: Current issues
•
•
•
•

Nature of relapse
What causes Relapse
How to minimize
What is beyond relapse prevention in
improving outcome

Relapse: ‘Life is never the same again’
• Expected in 70% patients after First episode
• 70% of patients show an incomplete remission
after first episode
• This includes Cognitive decline ( in 55%)
• persistence of negative symptoms ( in 41%),
• often associated with Social disabilities,
• Social Decline and a worsened QOL.
• Risk of relapse after an episode remained
increased throughout the life.
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Schizophrenia Relapse rates
Survival Analysis of optimal NL dose and
real world rehospitalization risk for
multiepisodic NL responsive schizophrenia

Cost of Relapse in Schizophrenia
By Peter J. Weiden and Mark Oltson
Schizophrenia Bulletin, Vol. 21, No. 3, 1995

Relapse : when and how it Occurs
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Not relapsed does not mean
good functioning. Nonrelapsing patients do have
disability, dysfunction and
poor QOL.
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Determinants of Relapse

Risk factors

Time to Remission

Possible
Mechanisms

Protective Factors:
personal resource, good premorbid adjustment, a
positive self concept & a competent social network

Effectiveness of intervention for Schizophrenia:
Relapse rate
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Efficacy and effectiveness of Antipsychotic
Medications: Annual Relapse Rate

Effectiveness of Antipsychotic Dugs in Schizophrenia
(Lieberman et al , 2005)

Cognitive behavior Therapy for residual symptoms in
Schizophrenia Patients in Community
( Dickerson & Lehman, 2005)

Combining Medication and Family
Education in Schizophrenia; Relapse Rates

Relapse rate in 2 years

Proportion surviving

with Oral Vs LA Depot APD combined with
psychosocial intervention, Schoolar et al , 2006

Months of treatment , N= 5- each Group

Schizophrenia PORT
Current practices

Are Antipsychotics superior to psychosocial & cognitive behavioural therapies
in relapse prevention of schizophrenia?
• Evidence is equivocal
Thus ,there is a clear case for integrated and
comprehensive therapy right from the day of
the first contact; irrespective of the clinical
settings; situations and alliances .

Striatal D2 Occupancy

Percentage change in CGI

Percentage Change in PANSS Positive
Striatal D2 Occupancy

Agid et al. Neuropsychopharmacology.2007.

Antipsychotic Response is a function of
5HT2a & D2 blocking Ratio

Genetics - Examples
• An example of how a genetic • Another example from the
British Journal of Psychiatry:
predisposition for
– Indicates that adopted
schizophrenia can be triggered
children with high
by environmental influences
genetic/biological risk for
can be seen in a research
schizophrenia (their mother
had schizophrenia) had an
study taken from Biological
86% lower rate of developing
Psychiatry, Volume 57:
– Indicates that people who had
multiple copies of a version of
the COMT gene and who
smoked marijuana had a 1,000%
increase in their risk of
developing schizophrenia

schizophrenia raised in a
healthy vs. a dysfunctional
family.
– Only 6% of the children
developed schizophrenia in
the healthy family.
– 37% of the children of the
dysfunctional families
developed schizophrenia

(as cited on www.schizophrenia.com).

Why does comorbidity develop??
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Why is Medication Not Sufficient?
• Neurodevelopmental dyfunction
• Subtle neurocognitive deficits from early
childhood
• Diffuse system disruption
• Timing of first exacerbation disrupts adult
socialization
• Residual primary and secondary negative
symptoms

Impact of Non-Adherence
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Negotiating Medications
Attitude, accept
ance, Belief, cul
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Team
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Nature of
illness,
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effects

Expressed emotion and psychiatric
relapse: a meta-analysis.

Community-Based Treatment of Schizophrenia and Other Severe Mental
Disorders: Treatment Outcomes
cumulative relapse/rehospitalization rates during 18 to 24 months in randomized controlled
trials of long-term family intervention for schizophrenia.

Kim T. Mueser, PhD, Gary R.
Bond, PhD, Robert E. Drake, MD, PhD
Medscape General Medicine 3(1), 2001

Specialized programs for relapse prevention are more effective in
identifying prodomal episodes before frank relapse
‘A Program for Relapse Prevention in Schizophrenia: A Controlled Study’

Marvin I. Herz, et al
Arch Gen Psychiatry. 2000;57:277-283.

Nature of Illness as Determinants of
Relapse

Biological mechanisms of relapse may not become fully
elucidated before the mechanisms of the schizophrenic
pathophysiology are clarified.

• low serotonergic and high dopaminergic
neurotransmission are associated with a relapse,
• possibly high noradrenergic neurotransmission plays
a role in short-term relapses.
• Role of Certain cytokines, which have rarely been
studied to date, seem to have an even higher impact
on schizophrenic relapse.

Biological studies and Relapse
Plasma HVA

Week following haloperidol withdrawal model, likelihood ratio p < 0.0005

Biological studies and Relapse
Plasma MHPG

Week following haloperidol withdrawal model, likelihood ratio p < 0.0005

Relevance of Neuro-cognitive deficits for
functional outcome in schizophrenia
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Can Neurocognitive Functioning Be
Improved with Psychosocial
Interventions?

Strategies for reducing
Cognitive Demands

Developmental and stress-related changes of neurotrophic
factor gene expression in an animal model of schizophrenia
Stress-diathesis model forms the theoretical context of
Risk-Vulnerability hypothesis
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Maximizing outcome and preventing relapse : The necessary steps
Work on acceptability
an dattitude

Support & Monitoring

Early
Intervention, Hospit
alization and
discharge

Optimize
Antipsychotic and
Cognitive enhancers

Family education and
family therapy

Early detection
and optimizing
treatment

Specific Suicide prevention
program & strict
monitoring for risk

Early Discharge with
high quality care plan

What can a psychiatrist do?

Program based Intervention for psychosis:
Advantages and Caution
• Much better than
Treatment as usual
• Response, Recovery,
outcome, Functioning &
quality of life is better
• Relapse is less,
• Disability and morbidity due
to side effect is reduced
• Caution : Continuity of care
is clinical and ethical issue

• Discharging patients out of
program is likely to
compromise quality of care.
• Caution : discharge if
remission has persisted for
more than 5-7 years &
• subject has become over
40 years of age
• family is nor dysfunctional
• Genetic loading is not very
high
• Low risk for suicide

Research needs for Relapse Prevention
Most Important ones :
• Biological Markers for
– Course of psychosis
– Responders Vs Non-responders
– Endophenotypes of side effects of medications
– Antipsychotic response

• Determinants of ‘Insight’ and ‘awareness’
• Biological pathways for Cognitive dysfunction
• Markers fro stress response in psychosis

Summary:
Relapse Can be effectively minimized
• Relapse is common and main issue in outcome
• It is part of biological nature of illness, mostly in first 5-7
years
• Treatment barriers and risk factors for relapse needs to be
identified and dealt with.
• Early Intervention, Education, Enhancing
Compliance, Qualitative assessments, Safety of
medication, Optimization of treatments are necessary
• Optimum Dose and adequate duration is a must.
• Program based Comprehensive and multidisciplinary
treatment needs to be managed

